T1	p 51 153	of previously untreated advanced breast cancer -- a cancer and leukemia group B study ( CALGB 8642 ) .
T2	p 533 714	in the Cancer and Leukemia Group B ( CALGB ) master metastatic breast cancer protocol . CALGB 8642 randomizes previously untreated metastatic breast cancer patients either to one of
T3	p 723 731	Phase II
T4	p 1258 1273	Patients had to
T5	p 1279 1329	histologically documented measurable breast cancer
T6	p 1358 1361	0-1
T7	p 1364 1435	Patients could not have had prior chemotherapy for metastatic disease .
T8	p 2295 2329	untreated breast cancer patients .
T9	p 2472 2480	patients
T10	i 6 15	Amonafide
T11	i 21 27	active
T12	i 204 208	acid
T13	i 788 840	standard cyclophosphamide-doxorubicin-5-fluorouracil
T14	i 849 868	immediate treatment
T15	i 874 928	standard cyclophosphamide-doxorubicin-5-fluorouracil .
T16	i 1451 1463	chemotherapy
T17	o 988 1030	survival , toxicity , and overall response
T18	o 1504 1531	visceral crisis . Amonafide
T19	o 1701 1742	hematotoxicity or lack thereof . Toxicity
T20	o 1757 1770	hematological
T21	o 1802 1817	or 4 leukopenia
T22	o 1842 1860	4 thrombocytopenia
T23	o 1875 1885	leukopenia
T24	o 1902 1938	thrombocytopenia . The response rate
T25	o 1964 1983	complete response .
T26	o 2014 2036	hematological toxicity
T27	o 2083 2103	leukopenia grade 3/4
T28	o 2176 2202	thrombocytopenia grade 3/4
T29	o 2418 2468	myelosuppression and response . Rates of responses